Scintigraphic Assessment Following Klean-Prep® or Moviprep®

NCT ID: NCT00896246

Last Updated: 2009-05-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-09-30
• Study Completion Date: 2006-11-30

Brief Summary

This was a phase 1, open-label, randomized study, designed to assess the impact of Moviprep® or Klean-Prep® on gastrointestinal transit. It was performed in two parallel groups with Part A in two groups of four subjects preceding Part B, which was performed in two groups of 12 subjects. Subjects attended a pre-study medical within 28 days of dosing and a post-study medical 5-10 days after the final dose. Within both Part A and Part B, subjects were required to attend the clinical unit for 2 study periods. Part A consisted of a baseline period to determine individual reference times for gastrointestinal transit. Part B was the test period in which gastrointestinal transit following the administration of the test preparations was assessed.

Conditions

Gastric Emptying; Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Klean-Prep®

1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.

Group Type: ACTIVE_COMPARATOR

Klean-Prep®

Intervention Type: DRUG

Four litres of solution administered orally as a divided dose.

Moviprep®

1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.

Group Type: EXPERIMENTAL

Moviprep®

Intervention Type: DRUG

Two litres of solution administered orally as a divided dose

Interventions

Klean-Prep®

Four litres of solution administered orally as a divided dose.

Intervention Type: DRUG

Moviprep®

Two litres of solution administered orally as a divided dose

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy males;

2. Aged 18-65 years;

3. Body Mass Index of 18-35 kg/m2;

4. Must be willing and able to participate in the whole study and must provide written informed consent.

Exclusion Criteria

1. Participation in a clinical research study involving investigational drugs or dosage forms within the previous 3 months;

2. Subjects who have previously been enrolled in this study;

3. Subjects who have ever sought advice from or been referred to a GP or counsellor for abuse or misuse of alcohol, non medical drugs, medicinal drugs or other substance abuse e.g. solvents;

4. Subjects who admit to any current or previous use of Class A drugs such as opiates, cocaine, ecstasy, LSD (d lysergic acid diethylamide) and intravenous amphetamines. Subjects who admit to occasional past use of cannabis will not be excluded as long as they have a negative drugs of abuse test and have abstained from cannabis use for at least 3 months;

5. Positive drugs of abuse test result;

6. Regular alcohol consumption > 21 units per week (1 Unit = ½ pint beer, a 25 mL shot of 40% spirit or a 125 mL glass of wine);

7. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening;

8. Radiation exposure from clinical trials, including that from the present study and from diagnostic x rays but excluding background radiation, exceeding 5 mSv in the last twelve months or 10 mSv in the last five years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study;

9. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the PMI;

10. History of gastrointestinal surgery (with the exception of appendectomy unless it was performed within the previous 12 months);

11. History of clinically significant cardiovascular, renal, hepatic, respiratory and particularly gastrointestinal disease, especially peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease or Irritable Bowel Syndrome;

12. Subjects with a hypersensitivity to any of the ingredients in either Moviprep® or Klean- Prep®;

13. Diarrhoea or constipation in the 7 days before the predicted first study day. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day.

14. Subjects will be excluded from the study if they are considered by the PMI to be at risk of transmitting, through blood or other body fluids, the agents responsible for AIDS (Acquired Immunodeficiency Syndrome), other sexually transmitted disease or hepatitis. This will be assessed by the use of a question which requires that a potential subject decides whether he fulfills any category included on a reference card. If the answer is 'yes', the subject is excluded from the study;

15. Positive HBV, HCV or HIV results;

16. Subjects receiving prohibited medication as described in Section 7.4. Subjects must not stop taking a prescribed medication for the purpose of entering the study;

17. Subjects with a history of phenylketonuria or glucose-6-phosphate dehydrogenase deficiency;

18. Failure to satisfy the PMI of fitness to participate for any other reason.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Norgine

INDUSTRY

Sponsor Role: lead

Responsible Party

Norgine Ltd

Principal Investigators

Hans-Jürgen Gruss, MD

Role: STUDY_DIRECTOR

Norgine

Philip Evans, MB ChB MRCS

Role: PRINCIPAL_INVESTIGATOR

Pharmaceutical Profiles Ltd

Locations

Pharmaceutical Profiles Ltd

Nottingham, , United Kingdom

Countries

United Kingdom

Other Identifiers

NRL994-01/2007 (GLO)

Identifier Type: -

Identifier Source: org_study_id